3 Growth Stocks with Insider Backing to Thrive in Volatile Markets

As markets grapple with inflation, rate uncertainty, and geopolitical risks, investors are seeking companies with two critical traits: insider confidence and secular growth tailwinds. Today's focus is on three U.S. stocks—Corcept Therapeutics (CORT), Astera Labs (ALAB), and CoreWeave (CW)—where insiders own up to 19.9% of shares, revenue growth is forecast to surpass 24% annually, and strategic bets are positioning them to dominate high-demand sectors. These are not just stocks to watch—they're opportunities to capitalize on undervalued growth engines.

1. Corcept Therapeutics (CORT): Cortisol Modulation's Quiet Billion-Dollar Play

Insider Ownership: 11.7%
Revenue Growth: 24.8% CAGR
Why It's a Buy: Corcept's drugs target cortisol dysregulation—a condition affecting millions with Cushing's syndrome, depression, and cancer-related fatigue. Its lead asset, relacorilant, is in late-stage trials, with data expected to redefine its $3 billion market cap.

The Insider Edge: Insiders haven't just held shares—they've doubled down. CEO Joseph Korb's 2023 stock purchases and recent clinical trial progress signal confidence in unlocking $1 billion+ in annual sales. With 39% annual earnings growth projected, CORT is a leveraged play on a niche but high-margin market.

2. Astera Labs (ALAB): The NVIDIA-Backed AI Infrastructure Leader

Insider Ownership: 15.8%
Revenue Growth: 24% CAGR
Why It's a Buy: Astera's AI-optimized networking hardware is the backbone of data centers powering generative AI models. Its Q1 net income ($31.8 million) marked a historic turnaround, and its collaboration with NVIDIA ensures it's embedded in the next wave of AI compute.

The Insider Edge: Founders and executives own nearly 16% of the company, and no major insider sales have occurred in 2025. With a 61.4% annual earnings growth forecast, ALAB is a rare blend of profitability and scalability in the AI infrastructure space.

3. CoreWeave (CW): Cloud Powerhouse Fueling OpenAI's Expansion

Insider Ownership: 19.9%
Revenue Growth: 420% YoY (Q1 2025)
Why It's a Buy: CoreWeave's AI cloud platform is the engine behind OpenAI's $11.9 billion deal and enterprise AI labs. While its Q1 loss ($1.49/share) reflects IPO-related costs, its $981.6 million in Q1 revenue—up 420% YoY—proves demand is explosive.

The Insider Edge: Insiders own nearly 20% of shares, with CEO Michael Intrator and key executives holding stakes worth $1.5 billion. This concentration of ownership aligns their interests with investors'—a critical signal in high-growth, capital-intensive sectors.

Why Now? Insider-Backed Growth in a Volatile World

These stocks aren't just riding sector trends—they're owned by the people who built them. In volatile markets, insider ownership above 10% acts as a shield against uncertainty. CORT's clinical progress, ALAB's partnerships, and CoreWeave's OpenAI ties are all de-risked bets on secular trends—healthcare innovation, AI infrastructure, and cloud scalability.

Act Now: All three trade at price-to-sales ratios well below their growth rates, offering a margin of safety. CORT's $3B valuation ignores relacorilant's potential; ALAB's 15x P/S ratio is a steal for a $159M revenue company; and CW's 420% growth, despite losses, suggests it's years ahead of its peers.

Final Call to Action

Investors often overlook the power of insider conviction in volatile markets. But when executives are doubling down on shares, and revenue is growing at 24–420% annually, the math is clear: CORT, ALAB, and CW are undervalued growth engines. With insider stakes acting as a catalyst, these stocks could deliver 28%+ upside as their strategic initiatives come to fruition. The question isn't whether to buy—it's why you're waiting.

Data as of May 2025. Past performance does not guarantee future results.